Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-01-26
2009-08-18
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S155000, C514S316000
Reexamination Certificate
active
07576101
ABSTRACT:
The application provides for methods and compositions for inhibiting demyelination, promoting remyelination and/or treating paralysis in a subject in need thereof. Preferably, such compositions include immunoglobulins (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small molecules, which when administered in an effective amount inhibits demyelination and/or promotes remyelination in a patient. The compositions and methods described herein can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination.
REFERENCES:
patent: 6060501 (2000-05-01), Wachtel et al.
patent: 6291453 (2001-09-01), Ashwell et al.
patent: 6362341 (2002-03-01), Thorsett et al.
patent: 6436904 (2002-08-01), Ashwell et al.
patent: 6489300 (2002-12-01), Thorsett et al.
patent: 6492421 (2002-12-01), Thorsett et al.
patent: 6525026 (2003-02-01), Thorsett et al.
patent: 6559127 (2003-05-01), Dappen et al.
patent: 6583139 (2003-06-01), Thorsett et al.
patent: 6586602 (2003-07-01), Thorsett et al.
patent: 6900179 (2005-05-01), Thorsett et al.
patent: 6939855 (2005-09-01), Yednock et al.
patent: 6949570 (2005-09-01), Ashwell et al.
patent: 7030114 (2006-04-01), Thorsett et al.
patent: 7166580 (2007-01-01), Dappen et al.
patent: 7288526 (2007-10-01), Thorsett et al.
patent: 7320960 (2008-01-01), Thorsett et al.
patent: 2002/0161006 (2002-10-01), Kawamura et al.
patent: 2003/0065185 (2003-04-01), Thorsett et al.
patent: 2004/0014677 (2004-01-01), Thorsett et al.
patent: 2005/0222119 (2005-10-01), Thorsett et al.
patent: 2005/0272668 (2005-12-01), Yednock et al.
patent: 98/53814 (1998-12-01), None
patent: 98/53817 (1998-12-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06437 (1999-02-01), None
patent: 00/44408 (2000-08-01), None
patent: 01/54690 (2001-08-01), None
patent: 02/02556 (2002-01-01), None
International Search Report dated Oct. 18, 2005 (2 pp.).
PCT Written Opinion of the International Search Authority dated Oct. 18, 2005 (3 pp.).
N. Tubridy et al., “The Effect of Anti-[Alpha]4 Integrin Antibody on Brain Lesion Activity in MS”, Neurology, Vol. 53, No. 3, pp. 466-472, Aug. 1999.
Franz X. Weilbach et al., “Disease Modifying Treatments for Multiple Sclerosis. What is on the Horizon?”, CNS Drugs, vol. 11, No. 2, pp. 133-157, Feb. 1999.
W. A. Sheremata et al., “A Safety and Pharmacokinetic Study of Intravenous Natalizumab in Patients with MS”, Neurology, vol. 52, No. 5, pp. 1072-1074, Mar. 1999.
Syed A. Rizvi et al, “Other Therapy Options and Future Strategies for Treating Patients with Multiple Sclerosis”, Neurology, vol. 63, (Suppl 6), pp. S47-S54, Dec. 2004.
Lin et al., “Specific and Dual Antagonists of α4β7Integrins”, Bioorganic and Medicinal Chemistry Letters, vol. 12, No. 2, Jan. 2002, pp. 133-136.
Dressen Darren B.
Farouz Francine S.
Freedman Stephen
Karlik Stephen J.
Konradi Andrei W.
Crowell & Moring LLP
Elan Pharmaceuticals Inc.
Henley, III Raymond J
LandOfFree
Composition for and treatment of demyelinating diseases and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for and treatment of demyelinating diseases and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for and treatment of demyelinating diseases and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4080098